Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
Merimepodib is a broad spectrum antiviral candidate that has been shown to have strong activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in preclinical studies. Findings from a study awaiting peer review showed that merimepodib, alone or in combination with remdesivir, was associated with a significant reduction in viral production in cell cultures.
The randomized, double-blind phase 2 study will compare the efficacy and safety of merimepodib to placebo in hospitalized adult patients with COVID-19 who are either on noninvasive ventilation/high flow oxygen devices or require supplemental oxygen. The study is expected to be conducted at multiple sites in the US, including 3 Mayo Clinic sites.
“I’m very pleased to be involved in this planned phase 2 study of merimepodib for the treatment of patients with COVID-19 disease,” said Andrew D. Badley, MD, Professor and Chair of Department of Molecular Medicine and the Enterprise Chair of COVID-19 Task Force. “We plan to begin enrollment of this trial as soon as practicable given the importance of finding solutions to this pandemic.”
For more information visit biosig.com.
This article originally appeared on MPR